Dataset Information

How people can become persuaded by weak messages presented by credible communicators: Not all sleeper effects are created equal.

ABSTRACT: The sleeper effect has been proposed to describe temporal changes in persuasion for messages associated with noncredible sources. The present research introduces a new kind of sleeper effect denoting increases in persuasion for weak messages associated with credible sources. This effect of the source was hypothesized to derive from attending to the message source rather than the message arguments and reconstructing delayed attitudes primarily on the basis of the source information. Findings from three experiments revealed that when the focus of attention was the communicator, there was a sleeper effect for the source. Specifically, during the time between an immediate follow up and a delayed follow up, persuasion increased when credible sources presented weak arguments. In contrast, when the focus of attention was the message arguments, a traditional sleeper effect emerged. That is, persuasion increased when strong arguments were presented by a noncredible communicator. These effects were mediated by relative recall of arguments versus source attributes and replicated with different message topics and lengths of delay.

SUBMITTER: Albarracin D

PROVIDER: S-EPMC8157953 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:Antibodies that block T cell inhibition via the immune checkpoints CTLA-4 and PD-1 have revolutionized cancer therapy during the last 15 years. T cells express additional inhibitory surface receptors that are considered to have potential as targets in cancer immunotherapy. Antibodies against LAG-3 and TIM-3 are currently clinically tested to evaluate their effectiveness in patients suffering from advanced solid tumors or hematologic malignancies. In addition, blockade of the inhibitory BTLA receptors on human T cells may have potential to unleash T cells to effectively combat cancer cells. Much research on these immune checkpoints has focused on mouse models. The analysis of animals that lack individual inhibitory receptors has shed some light on the role of these molecules in regulating T cells, but also immune responses in general. There are current intensive efforts to gauge the efficacy of antibodies targeting these molecules called immune checkpoint inhibitors alone or in different combinations in preclinical models of cancer. Differences between mouse and human immunology warrant studies on human immune cells to appreciate the potential of individual pathways in enhancing T cell responses. Results from clinical studies are not only highlighting the great benefit of immune checkpoint inhibitors for treating cancer but also yield precious information on their role in regulating T cells and other cells of the immune system. However, despite the clinical relevance of CTLA-4 and PD-1 and the high potential of the emerging immune checkpoints, there are still substantial gaps in our understanding of the biology of these molecules, which might prevent the full realization of their therapeutic potential. This review addresses PD-1, CTLA-4, BTLA, LAG-3, and TIM-3, which are considered major inhibitory immune checkpoints expressed on T cells. It provides summaries of our current conception of the role of these molecules in regulating T cell responses, and discussions about major ambiguities and gaps in our knowledge. We emphasize that each of these molecules harbors unique properties that set it apart from the others. Their distinct functional profiles should be taken into account in therapeutic strategies that aim to exploit these pathways to enhance immune responses to combat cancer.

Dataset Information

How people can become persuaded by weak messages presented by credible communicators: Not all sleeper effects are created equal.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure